Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Open accessThe DOI matches its Crossref record; 177 of the 179 references it cites were found in a registry or an index; 83 of the 280 sources its claims cite were checked for support.
Abstract
Treatment-resistant depression (TRD) is a term used to describe a particular type of major depressive disorder (MDD). There is no consensus about what defines TRD, with various studies describing between 1 and 4 failures of antidepressant therapies, with or without electroconvulsive therapy (ECT). That is why TRD is such a growing concern among clinicians and researchers, and it explains the necessity for investigating novel therapeutic targets beyond conventional monoamine pathways. An imbalance between two primary central nervous system (CNS) neurotransmitters, L-glutamate and γ-aminobutyric acid (GABA), has emerged as having a key role in the pathophysiology of TRD. In this review, we provide an evaluation and comprehensive review of investigational antidepressants targeting these two systems, accessing their levels of available evidence, mechanisms of action, and safety profiles. N-methyl-D-aspartate (NMDA) receptor antagonism has shown the most promise amongst the glutamatergic targets, with ketamine and esketamine (Spravato) robustly generating responses across trials. Two specific NMDA-glycine site modulators, D-cycloserine (DCS) and apimostinel, have also generated promising initial safety and efficacy profiles, warranting further investigation. Combination dextromethorphan-bupropion (AXS-05/Auvelity) displays a unique mechanism of action and demonstrated positive results in particular applicability in subpopulations with cognitive dysfunction. Currently, the most promising GABA modulators appear to be synthetic neurosteroid analogs with positive GABAA receptor modulation (such as brexanolone). Overall, advances in the last decade provide exciting perspectives for those who do not improve with conventional therapies. Of the compounds reviewed here, three are approved by the Food and Drug Administration (FDA): esketamine (Spravato) for TRD, Auvelity (dextromethorphan-bupropion) for major depressive disorder (MDD), and brexanolone (Zulresso) for post-partum depression (PPD). Notably, some concerns have arisen with esketamine and brexanolone, which will be detailed in this study.
Overview
CoChat Summary
TL;DR
This review evaluates investigational pharmacotherapies targeting glutamate–GABA neurotransmission for treatment-resistant depression (TRD), concluding that NMDA receptor antagonism—especially ketamine and esketamine—has the strongest evidence, while synthetic neurosteroid GABA-A modulators are the most promising GABAergic agents. Three reviewed compounds are FDA-approved: esketamine for TRD, dextromethorphan–bupropion (Auvelity) for MDD, and brexanolone for postpartum depression.
Key findings
- TRD lacks a consensus definition; the modal definition is lack of response or remission after two adequate antidepressant trials, but only 17% of studies implement these criteria, and approximately one-third of depressed patients fail to remit even after four adequate therapeutic trials.
- Ketamine has robust evidence: a single dose can alleviate depressive symptoms for up to seven days with effects peaking at 24 h, and repeated infusions maintain effects for two to three weeks in MDD; a meta-analysis favored intravenous ketamine over intranasal esketamine for response (RR = 3.01 vs. 1.38), remission (RR = 3.70 vs. 1.47), and lower dropouts (RR = 0.76 vs. 1.37).
- Esketamine nasal spray was approved in 2019 for TRD after five phase III randomized double-blind placebo-controlled trials and one open-label trial; a long-term open-label study reported sustained improvement at 2 years, with 0.6% discontinuing for worsening depression and 0.2% for suicidal ideation, though one successful suicide occurred.
- Among GABA modulators, brexanolone is FDA-approved for postpartum depression, and zuranolone showed significant clinical improvements at day 3 and day 42 in MDD and at days 3, 15, 28, and 45 in 196 patients with postpartum depression; zuranolone was subsequently FDA-approved for postpartum depression.
Methods
- Narrative review of clinical studies up to September 2023 of investigational compounds targeting glutamatergic and/or GABAergic systems as their primary antidepressant mechanism, including compounds with evidence of antidepressant efficacy in at least one successful clinical trial.
- Evidence levels for antidepressant efficacy are summarized in Tables 1–3; psychedelics ayahuasca and psilocybin are mentioned but not formally included because their direct glutamate/GABA modulation in relation to antidepressant efficacy is unclear.
- The paper does not report a systematic search strategy, databases, inclusion/exclusion criteria, or quantitative synthesis; this is evident from the Methods section.
Limitations
- Stated: no clear consensus definition of TRD, with only 17% of studies using the modal two-adequate-trial definition.
- Stated across trials: inability to effectively blind subjects and raters to ketamine/esketamine, homogenous samples, short durations, limited real-world feasibility, high dropout in some esketamine trials, and safety concerns including suicidality and REMS restrictions for esketamine and brexanolone.
- Evident from the text: as a narrative review, it lacks a systematic search and meta-analytic synthesis; many compounds have small samples, short durations, and virtually identical designs, requiring larger and longer randomized controlled trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
36 Valid · 8 Not valid · 132 Not checked · 20 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 4. Clinical Studies with Glutamate Modulators in TRD > 4.1. Ketamine and Similar Compounds
What the sources say
- Disputedcites [111] Fedgchin, 2019, Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined with a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1), Int. J. Neuropsychopharmacol. sourceExperimental — accuracy not yet measured
Our copy confirms the factual kernel — TRANSFORM-1's primary endpoint was not met (esketamine 84 mg/antidepressant vs antidepressant/placebo: LS mean difference -3.2 [-6.88, 0.45], 2-sided P = .088; Abstract Results and Study Results) — but the paper draws the opposite conclusion from the claim: both the Abstract Conclusions and the Discussion summary state that the study 'provides supportive evidence for the safety and efficacy of esketamine nasal spray' in TRD, noting treatment effects for both esketamine doses (-3.2 and -4.1) exceeded the ~2-point difference considered clinically meaningful, nominal P = .027 for 56 mg, and numerically favorable key secondary and subgroup results (Discussion, Table 4 post hoc pooled-dose difference -3.8, 95% CI -6.92 to -0.70). Saying the study 'did not support' adjunctive esketamine's antidepressant efficacy therefore contradicts what the source itself asserts; the Discussion only attributes the lack of statistical significance to methodological factors (3-fold higher withdrawal in the 84 mg arm, unexpected antidepressant/placebo improvement, 1/3 placebo randomization). (LLM, conf=0.72)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Due to its short half-life, DM lacks AD efficacy as a monotherapy, but in conjunction with quinidine, a CYP2D6 enzyme inhibitor that limits DM metabolism, it produces more lasting AD effects [148,149].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 4. Clinical Studies with Glutamate Modulators in TRD > 4.2. Dextromethorphan and Similar Compounds
What the sources say
- Disputedcites [148] Nguyen, L., Robson, M.J., Healy, J.R., Scandinaro, A.L., and Matsumoto, R.R. (2014). Involvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan. PLoS ONE, 9. sourceExperimental — accuracy not yet measured
The Results (Effects of CYP2D6 Inhibitor Quinidine on Dextromethorphan Dose Response; page unavailable) report that dextromethorphan alone at 30 mg/kg produced a significant antidepressant-like effect in mice. The 10 mg/kg dose was not significant alone, and quinidine potentiated its effect, but those findings do not support the categorical claim that dextromethorphan lacks efficacy as a monotherapy due to a short half-life. The study does not establish clinical efficacy in humans. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [149] Nguyen, 2015, Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice, Behav. Brain Res. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“An imbalance between two primary central nervous system (CNS) neurotransmitters, L-glutamate and γ-aminobutyric acid (GABA), has emerged as having a key role in the pathophysiology of TRD.”
- Also stated in: § 2. Glutamate and GABA Dysfunction in Depression · boosted
“Glutamatergic and GABAergic dysfunction in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) has been extensively implicated in both MDD and TRD [16,17,18,19,20,21,22,23,24,25].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > Abstract
What the sources say
- Not checked yetcites [16] Abdallah, 2017, Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment, Biol. Psychiatry Cogn. Neurosci. Neuroimaging
- Not checked yetcites [17] Berman, 2011, Depression, rumination and the default network, Soc. Cogn. Affect. Neurosci. source
- Not checked yetcites [18] Buckner, 2008, The Brain’s Default Network: Anatomy, Function, and Relevance to Disease, Ann. N. Y. Acad. Sci. source
- Partly supportedcites [19] Gabbay, 2012, Anterior Cingulate Cortexγ-Aminobutyric Acid in Depressed Adolescents: Relationship to Anhedonia, Arch. Gen. Psychiatry sourceExperimental — accuracy not yet measured
The introduction links dysregulation of GABA and glutamate to anhedonia and MDD pathophysiology, and the Comment says the two systems may be linked. The study concerns adolescents with MDD, not treatment-resistant depression (TRD), and does not establish that an imbalance between the neurotransmitters has a key role in TRD. (LLM, conf=0.86)
- Not checked yetcites [20] Horn, 2010, Glutamatergic and resting state functional connectivity correlates of severity in major depression—The role of pregenual anterior cingulate cortex and anterior insula, Front. Syst. Neurosci.
- Partly supportedcites [21] Isaacson, 2011, How Inhibition Shapes Cortical Activity, Neuron sourceExperimental — accuracy not yet measured
In “Inhibition’s impact on membrane potential and excitability” (page unavailable), the paper identifies glutamate with cortical excitation and GABA with inhibition. In “The ‘balance’ of excitation and inhibition” (page unavailable), it says disrupting their relationship can impair cortical activity. It does not connect that imbalance to treatment-resistant depression or establish a key role in its pathophysiology. (LLM, conf=0.83)
- Could not verifycites [22] Pizzagalli, 2018, Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial, JAMA Psychiatry sourceExperimental — accuracy not yet measured
The Discussion mentions possible glutamatergic abnormalities underlying altered rACC activity, but does not discuss an imbalance between glutamate and GABA. Searches for GABA and neurotransmitter imbalance found no passage linking that imbalance to treatment-resistant depression; the Limitations section says it is unclear whether the study's findings generalize to treatment-resistant samples. (LLM, conf=0.74)
- Partly supportedcites [23] Price, 2009, Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder, Biol. Psychiatry sourceExperimental — accuracy not yet measured
The Results report an elevated occipital glutamate-plus-glutamine-to-GABA (Glx:GABA) ratio in TRD, and the Discussion describes the findings as consistent with amino acid neurotransmitter dysfunction. But the Discussion says the study cannot establish cause and effect; it does not establish that an L-glutamate–GABA imbalance has a key role in TRD pathophysiology. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Partly supportedcites [24] Walton, N., and Maguire, J. (2019). Allopregnanolone-based treatments for postpartum depression: Why/how do they work?. Neurobiol. Stress, 11. sourceExperimental — accuracy not yet measured
The section “Diverse etiology of postpartum depression with relevance to allopregnanolone” says GABAergic deficits could contribute to depression and discusses a GABAergic hypothesis for major depressive disorder. It does not establish a glutamate–GABA imbalance as a key mechanism in treatment-resistant depression (TRD); the glutamate search found it only in a reference title. No page number was provided for these passages. (LLM, conf=0.86)
- Could not verifycites [25] Zhou, 2020, Rumination and the default mode network: Meta-analysis of brain imaging studies and implications for depression, NeuroImage sourceExperimental — accuracy not yet measured
The paper’s Abstract and Section 4.3 discuss default-mode-network activity during rumination and implications for depression, not a glutamate–GABA imbalance in treatment-resistant depression. Searches for L-glutamate, GABA, and treatment-resistant depression found no passage in our copy addressing the claimed mechanism. (LLM, conf=0.75)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2. Glutamate and GABA Dysfunction in Depression · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Specifically, cortical GABAergic disinhibition in depressive disorders co-occurs with increases in glutamatergic gene expression in the DMN [24,26,27,28,29,30,31,32].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 2. Glutamate and GABA Dysfunction in Depression
What the sources say
- Partly supportedcites [24] Walton, N., and Maguire, J. (2019). Allopregnanolone-based treatments for postpartum depression: Why/how do they work?. Neurobiol. Stress, 11. sourceExperimental — accuracy not yet measured
In “Diverse etiology of postpartum depression with relevance to allopregnanolone” (page not available), the review discusses GABAergic deficits in depression and reports a correlation between GABA levels and default mode network connectivity in women with postpartum depression. It does not report increased glutamatergic gene expression in the DMN or establish that such an increase co-occurs with cortical GABAergic disinhibition. (LLM, conf=0.84)
- Partly supportedcites [26] Deligiannidis, 2019, Resting-state functional connectivity, cortical GABA, and neuroactive steroids in peripartum and peripartum depressed women: A functional magnetic resonance imaging and spectroscopy study, Neuropsychopharmacology sourceExperimental — accuracy not yet measured
The Discussion (p. 7) notes that major depressive disorder has been associated with reduced cortical GABA, while reporting no between-group GABA difference in this study. The paper reports altered DMN connectivity in postpartum depression (p. 1), but it does not report increased glutamatergic gene expression in the DMN or its co-occurrence with GABAergic disinhibition. (LLM, conf=0.86)
- Not checked yetcites [27] Gray, 2015, Sex differences in glutamate receptor gene expression in major depression and suicide, Mol. Psychiatry source
- Not checked yetcites [28] Levinson, 2010, Evidence of Cortical Inhibitory Deficits in Major Depressive Disorder, Biol. Psychiatry source
- Not checked yetcites [29] Papp, 1994, Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression, Eur. J. Pharmacol. source
- Partly supportedcites [30] Seney, 2018, Opposite Molecular Signatures of Depression in Men and Women, Biol. Psychiatry sourceExperimental — accuracy not yet measured
The Introduction (page not available) reports reduced expression of the GABA-neuron marker somatostatin and increased expression of glutamate-related genes in women with major depressive disorder; it reports decreased expression of those glutamate-related genes in men. The paper does not establish GABAergic disinhibition co-occurring with glutamatergic increases in the default mode network, and its findings are sex-specific rather than a general pattern across depressive disorders. (LLM, conf=0.86)
- Partly supportedcites [31] Tripp, 2011, Reduced somatostatin in subgenual anterior cingulate cortex in major depression, Neurobiol. Dis. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes evidence of impaired excitation–inhibition balance and reduced cortical GABA in major depression. The Discussion (page unavailable) reports reduced somatostatin, an inhibitory peptide, in the subgenual anterior cingulate cortex. The paper does not report co-occurring increases in glutamatergic gene expression or establish that pattern across the default mode network. (LLM, conf=0.86)
- Partly supportedcites [32] Zhao, 2018, Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide, J. Psychiatr. Res. sourceExperimental — accuracy not yet measured
The Results (section 3.3, p. 6) report increased glutamatergic gene expression in the DLPFC of patients with MDD and in the ACC of patients with MDD who died by suicide. They also report increases in GABAergic markers in those groups, rather than demonstrating cortical GABAergic disinhibition. The paper examines these prefrontal regions, not gene expression across the default mode network. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Diminishing returns demonstrated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial underscore the need for novel treatment avenues targeting the pathophysiological source of treatment resistance [4].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 1. Introduction: The Problem of TRD
What the sources say
- Partly supportedcites [4] Trivedi, 2006, Medication Augmentation after the Failure of SSRIs for Depression, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The introduction (page unavailable) identifies this as a STAR*D second-step study for patients who did not remit with citalopram, and Symptom Outcomes reports remission rates of about 30% with either augmentation drug. The paper does not compare remission across successive treatment steps to demonstrate diminishing returns, nor does it call for novel treatments targeting the pathophysiology of resistance. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
79 more claims · 21 with their cited sources checked
Create a free account to see all 196 claims and to verify the 197 references still open.
- It may state two separate claims as one. 100
- Probably not a substantial claim. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common adverse effects include dissociation, dizziness, and blood pressure (BP) elevation [52,53,55].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, esketamine nasal spray demonstrates rapid efficacy in treatment-resistant depression (TRD), with improvements emerging within hours to days and sustained by maintenance dosing [53].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [53]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > Abstract
“Of the compounds reviewed here, three are approved by the Food and Drug Administration (FDA): esketamine (Spravato) for TRD, Auvelity (dextromethorphan-bupropion) for major depressive disorder (MDD), and brexanolone (Zulresso) for post-partum depression (PPD).”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 6. Conclusions
“Of the compounds reviewed here, two are FDA-approved: esketamine (Spravato) for TRD and BRX (Zulresso) for PPD.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 6. Conclusions
“N2O was discontinued from development due to side effects and abuse potential.”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 4. Clinical Studies with Glutamate Modulators in TRD > 4.1. Ketamine and Similar Compounds
“Several trials with N2O are currently enrolling for depression (MDD and bipolar), suicidal ideation, post-traumatic stress disorder, and others [129].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 6. Conclusions
“Zuranolone is scheduled to receive a response from FDA in August 2023 about the approval or not since the application has been granted priority by the agency [193].”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 5. Clinical Studies with GABA Modulation in TRD > GABAA Receptor Positive Modulation
“Due to those very recent findings, Zuranolone was approved by the FDA for the treatment of PPD [191].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > Abstract
“Of the compounds reviewed here, three are approved by the Food and Drug Administration (FDA): esketamine (Spravato) for TRD, Auvelity (dextromethorphan-bupropion) for major depressive disorder (MDD), and brexanolone (Zulresso) for post-partum depression (PPD).”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 5. Clinical Studies with GABA Modulation in TRD > GABAA Receptor Positive Modulation
“Due to those very recent findings, Zuranolone was approved by the FDA for the treatment of PPD [191].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 3. Methods: Clinical Studies of Investigational Compounds Targeting Glutamate and GABA
“All proceeding compounds demonstrate evidence of antidepressant efficacy in at least one successful clinical trial, though not all have progressed through the final stages of drug development.”
§ Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression > 4. Clinical Studies with Glutamate Modulators in TRD > 4.1. Ketamine and Similar Compounds
“At 6 weeks, decreases in MADRS scores were noted from baseline, but without reaching statistical significance when compared to the placebo group, failing the primary endpoint, and, for the secondary endpoints, mood and functioning and cognitive impairment, it has also failed in separate from the placebo group.”
Citations
Cites
The Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 3×
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 2×
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
BackgroundResultNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · cited 1×
“…glutamate/BDNF signaling via TrkB. Notably, multiple serotonergic hallucino-gens have also demonstrated preliminary efficacy in TRD [55,56] and impart downstream glutamatergic effects (as well as robust spinogenesis and dendritogenesis), which are dependent on intact TrkB signaling [57,58].”
BackgroundSynaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 2×
“In depressed patients, synaptic plasticity pathways have been shown to be disrupted in the PFC and hippocampi, correlated with α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and NMDA receptor abnormalities [45,46].”
BackgroundHow Inhibition Shapes Cortical Activity
Isaacson, J. S., & Scanziani, M. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.027 · Cited by 1,678
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 1×
“…glutamate/BDNF signaling via TrkB. Notably, multiple serotonergic hallucino-gens have also demonstrated preliminary efficacy in TRD [55,56] and impart downstream glutamatergic effects (as well as robust spinogenesis and dendritogenesis), which are dependent on intact TrkB signaling [57,58].”
Background
Research works printed but not linked: 2
- Sage Therapeutics (2023, September 04). Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder. Available online: https://www.businesswire.com/news/home/20191205005375/en/4676027/Sage-Therapeutics-Reports-Topline-Results-from-Pivotal-Phase-3-MOUNTAIN-Study-of-SAGE-217-in-Major-Depressive-Disorder.
- Sage Therapeutics (2023, September 04). Business Wire. Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression. Available online: https://www.businesswire.com/news/home/20230205005025/en/.
Cited by
From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine
Toader, C., Șerban, M., Munteanu, O., Covache-Busuioc, R.-A., Enyedi, M., Ciurea, A. V., & Tătaru, C. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094271 · Cited by 184
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 106
“The balance between the inhibitory GABAergic and excitatory glutamatergic neurotransmitter systems [25] is very essential in brain functioning since all neurons and glial cells have glutamate and GABA receptors [155].”
BackgroundFrom Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation
Krasner, H., Ong, C. V., Hewitt, P., & Vida, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073219 · Cited by 42
“Increasing evidence suggests that TRD may be linked to excitatory and inhibitory neurotransmission disruptions, particularly glutamatergic overactivity and GABAergic deficits [52].”
Astrocytic GABAergic Regulation in Alcohol Use and Major Depressive Disorders
Ali, D. N., Ali, H. M., Lopez, M. R., Kang, S., & Choi, D. (2024) · Cells · doi:10.3390/cells13040318 · Cited by 30
“Brexanolone (SAGE-547) and zuranolone (SAGE-217) are investigational drugs that target GABA A Rs and have shown promise in clinical trials for postpartum depression [165] (Table 2).”
BackgroundChang, Z., Zhu, Y., Wang, P., Du, L., Wu, M., Wang, X., Kong, C., Huang, D., Xie, R., Guo, J., et al. (2025) · 中国科学通报:英文版 · doi:10.1016/j.scib.2025.04.010 · Cited by 20
Metadata
- Authors
- Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX 77054, USA
- John S. Dunn Behavioral Sciences Center at UTHealth Houston, 5615 H.Mark Crosswell Jr St, Houston, TX 77021, USA
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2023-11-07
- Volume
- 16
- Issue
- 11
- Pages
- 1572
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC10675154
- OpenAlex
- W4388453068
- Cited by
- 48
- References
- 179
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 12
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, major depressive disorder, NMDA receptor antagonism, ketamine, esketamine, D-cycloserine, GABA-A receptor modulation, brexanolone, postpartum depression, antidepressant mechanism, drug safety profile
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression. https://app.cochat.ai/papers/10.3390/ph16111572
- The paper
- Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023). Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression. Pharmaceuticals. https://doi.org/10.3390/ph16111572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.